A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.

Entera Bio Ltd. ENTX

Weak broader-coverage candidate · Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical

On FrontierLab's discovery record since 2026-07-27 (3 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)

Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Weak" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-07-28), not the curated Frontier signal.

⚡ Surfaced on a price move — momentum is where to look, not a buy signal. The move that surfaced this name does not make it a good entry.

⚠ Pump risk: parabolic/spike characteristics detected in the screen flags. Treat any positive grade with extra skepticism.

Key quality signals

Revenue growth (YoY)	-100%
Gross margin	—
Gross profits / assets	0
Rule of 40	—
Net margin	—
Cash runway (months)	5.2
PEG	—
Price / sales	—

Quality checklist

✗ Revenue growth — -100% (pass ≥ 20%)
✗ Gross profits / assets — 0 (pass ≥ 0.33)
✗ Cash generation
✗ Share dilution — 10.1%

Fundamentals — snapshot as of 2026-07-28

Stage	Established
Share issuance (YoY)	10.1% · heavy issuance
Moat	—
TAM	—
P/E (trailing)	—
EPS (trailing)	$-0.26
Burn multiple	—
Gross-margin trend (pts)	—
Cash / assets	0.32
Net debt / EBITDA	—
Statements as of	Q1 FY2026 · filed 2026-05-08

Momentum context — a snapshot from 2026-07-28, not current

Price at surface	$3.92 (as of 2026-07-28)
52-week range	$0.91 – $4.2
% off 52-wk high	-6.7%
RSI (14)	90
Relative volume	18.7×

Risk flags

Cash runway ~5 months at current burn — a dilutive raise looks imminent.Heavy dilution (~10%/yr) — top-decile share issuers have historically underperformed.Parabolic one-day spike (+91%) in the last month — extreme single-day moves tend to mean-revert.Volume 18.7× normal alongside the move — attention-crowded names tend to reverse over the following weeks.

← All broader-coverage names · Curated names → · Open the interactive screener →

Data as of 2026-07-28 (end-of-day). How grades are computed →